abrdn Life Sciences Investors
HQL
67 hedge funds and large institutions have $74.4M invested in abrdn Life Sciences Investors in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 30 increasing their positions, 14 reducing their positions, and 10 closing their positions.
114% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 14
10% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 10
0% more funds holding
Funds holding: 67 → 67 (0)
0.84% less ownership
Funds ownership: 16.8% → 15.96% (-0.84%)
50% less capital inflows, than outflows
Capital inflows: $4.1M | Capital outflows: $8.25M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
+$1.22M |
| 2 |
Weiss Asset Management
Boston,
Massachusetts
|
+$395K |
| 3 |
Raymond James & Associates
St Petersburg,
Florida
|
+$348K |
| 4 |
NewEdge Advisors
New Orleans,
Louisiana
|
+$294K |
| 5 |
Cetera Advisor Networks
El Segundo,
California
|
+$271K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Advisors Asset Management
Monument,
Colorado
|
-$1.46M |
| 2 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
-$1.43M |
| 3 |
Stephens Inc
Little Rock,
Arkansas
|
-$1.05M |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$1.02M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$830K |
HQL Hedge Fund Activity: Q4 2021 in Review
67 of the 6,521 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q4 2021, worth a combined $74.4M — down 13% from $85.1M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new HQL positions and 10 closed out — a net gain of 1 holder — while 30 added to existing stakes and 14 trimmed.
The largest buyer was LPL Financial, adding an estimated $1.22M. The largest seller was Advisors Asset Management, cutting an estimated $1.46M.
- 67 institutional investors held abrdn Life Sciences Investors (HQL) as of Q4 2021, unchanged from Q3 2021.
- Funds reported $74.4M of abrdn Life Sciences Investors stock for Q4 2021, down 13% quarter-over-quarter.
- 11 funds opened new abrdn Life Sciences Investors positions in Q4 2021 and 10 closed out, a net change of +1 holder.
- The largest abrdn Life Sciences Investors buyer in Q4 2021 was LPL Financial, an estimated $1.22M added.
- The largest abrdn Life Sciences Investors seller in Q4 2021 was Advisors Asset Management, an estimated $1.46M sold.
Based on aggregated 13F filings for Q4 2021.